Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo + Yervoy
nivolumab + ipilimumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment for metastatic non-small cell lung cancer with tumor PD-L1 expression of at least 1% by an FDA-approved test and no EGFR or ALK genomic tumor aberrations.
LAMPGEN ANALYSIS
Why it matters
Added a first-line chemotherapy-free dual immunotherapy regimen for this PD-L1-defined population.
What research teams should watch
Verify PD-L1 and driver results before treatment and keep immune toxicity triage available between visits.
PRIMARY RECORDS